The oncology landscape is transforming at an unprecedented rate. Join industry leaders from Pharma, Biotech, and VC as they dive into strategic portfolio evolution, company creation, and investment trends shaping tomorrow's therapies.
Key themes will explore:
The evening will conclude with a networking apéro bringing together professionals from business development, licensing, R&D, and investment.
Featured Speakers
Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm. Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen (NASDAQ: AMGN)) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX: MOLN).
Panel Discussion
Stefanie Granado rejoined Novartis in October 2024 as Therapeutic Area Head, Oncology International. Prior to returning, Stefanie was with Takeda, where Stefanie served as Head of the US Oncology Business Unit after leading the Oncology organization across Europe and Canada. Stefanie also held General Manager roles for Iberia (Spain and Portugal) and Switzerland at Takeda and Shire.
Earlier in Stefanie's career at Novartis, Stefanie led the Novartis Vaccines Division in Colombia and Venezuela and was responsible for Market Access and Public Affairs across Latin America. Stefanie holds a PhD in Cultural Epidemiology from the Swiss Tropical Institute, a Master of Arts from the University of Basel, and brings a background in management consulting.
Guillaume Cettou is Executive Director, Oncology Translational Medicine at GSK, where he leads portfolio strategy and precision diagnostics for the oncology pipeline. His work sits at the intersection of asset strategy, business development, translational science, and AI — using technology and data to advance precision medicine from early discovery through clinical development.
Before GSK, Guillaume held roles at SOPHiA GENETICS, Amgen, and McKinsey & Company, spanning business development, drug development, commercialization and strategy consulting. This trajectory gives him a distinctive vantage point on the healthcare ecosystem: from pharma R&D to commercial execution, supported by strategy and innovation.
We look forward to welcoming you for an engaging evening of knowledge-sharing and networking.
For this event, we will welcome participants at Reception in Building 7. The reception desk for Auditorium 4 is located in Building 7, and attendees will be directed from there to the auditorium.
2023 © Swiss HLG | by evago.fr
Cookies settings
